stoxline Quote Chart Rank Option Currency Glossary
  
Lucid Diagnostics Inc. (LUCD)
0.84  -0.04 (-4.53%)    07-18 16:00
Open: 0.879
High: 0.879
Volume: 97,521
  
Pre. Close: 0.8799
Low: 0.839
Market Cap: 45(M)
Technical analysis
2024-07-18 4:22:24 PM
Short term     
Mid term     
Targets 6-month :  1.07 1-year :  1.25
Resists First :  0.92 Second :  1.07
Pivot price 0.83
Supports First :  0.77 Second :  0.68
MAs MA(5) :  0.86 MA(20) :  0.81
MA(100) :  0.92 MA(250) :  1.19
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  69.9 D(3) :  74.6
RSI RSI(14): 51.7
52-week High :  1.72 Low :  0.62
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ LUCD ] has closed below upper band by 45.6%. Bollinger Bands are 38.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.88 - 0.88 0.88 - 0.89
Low: 0.83 - 0.83 0.83 - 0.84
Close: 0.83 - 0.84 0.84 - 0.85
Company Description

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Headline News

Tue, 16 Jul 2024
Analyzing Fractyl Health (NASDAQ:GUTS) & Lucid Diagnostics (NASDAQ:LUCD) - American Banking and Market News

Thu, 11 Jul 2024
Lucid Diagnostics Launches New Corporate Website - PR Newswire

Thu, 04 Jul 2024
Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data - Yahoo Finance

Tue, 02 Jul 2024
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population – Company Announcement - FT.com - Financial Times

Wed, 12 Jun 2024
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing - PR Newswire

Mon, 13 May 2024
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 0 (M)
Shares Float 52 (M)
Held by Insiders 1.645e+007 (%)
Held by Institutions 67.3 (%)
Shares Short 285 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.257e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 78.1 %
Return on Equity (ttm) -69.3 %
Qtrly Rev. Growth 2.98e+006 %
Gross Profit (p.s.) 85.79
Sales Per Share -176.28
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -38 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow -1.77
Stock Dividends
Dividend 0
Forward Dividend 594300
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android